Literature DB >> 19458243

p53-Dependent transcriptional control of cellular prion by presenilins.

Bruno Vincent1, Claire Sunyach, Hans-Dieter Orzechowski, Peter St George-Hyslop, Frédéric Checler.   

Abstract

The presenilin-dependent gamma-secretase processing of the beta-amyloid precursor protein (betaAPP) conditions the length of the amyloid beta peptides (Abeta) that accumulate in the senile plaques of Alzheimer's disease-affected brains. This, together with an additional presenilin-mediated epsilon-secretase cleavage, generates intracellular betaAPP-derived fragments named amyloid intracellular domains (AICDs) that regulate the transcription of several genes. We establish that presenilins control the transcription of cellular prion protein (PrP(c)) by a gamma-secretase inhibitor-sensitive and AICD-mediated process. We demonstrate that AICD-dependent control of PrP(c) involves the tumor suppressor p53. Thus, p53-deficiency abolishes the AICD-mediated control of PrP(c) transcription. Furthermore, we show that p53 directly binds to the PrP(c) promoter and increases its transactivation. Overall, our study unravels a transcriptional regulation of PrP(c) by the oncogene p53 that is directly driven by presenilin-dependent formation of AICD. Furthermore, it adds support to previous reports linking secretase activities involved in betaAPP metabolism to the physiology of PrP(c).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458243      PMCID: PMC6665908          DOI: 10.1523/JNEUROSCI.0789-09.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  20 in total

1.  The extracellular regulated kinase-1 (ERK1) controls regulated alpha-secretase-mediated processing, promoter transactivation, and mRNA levels of the cellular prion protein.

Authors:  Moustapha Cissé; Eric Duplan; Marie-Victoire Guillot-Sestier; Joaquim Rumigny; Charlotte Bauer; Gilles Pagès; Hans-Dieter Orzechowski; Barbara E Slack; Frédéric Checler; Bruno Vincent
Journal:  J Biol Chem       Date:  2011-05-17       Impact factor: 5.157

2.  Proteolytic processing of the prion protein in health and disease.

Authors:  Hermann C Altmeppen; Berta Puig; Frank Dohler; Dana K Thurm; Clemens Falker; Susanne Krasemann; Markus Glatzel
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

Review 3.  Structural and mechanistic commonalities of amyloid-β and the prion protein.

Authors:  Bianca Da Costa Dias; Katarina Jovanovic; Danielle Gonsalves; Stefan F T Weiss
Journal:  Prion       Date:  2011-07-01       Impact factor: 3.931

4.  β-amyloid oligomers and prion protein: Fatal attraction?

Authors:  Gianluigi Forloni; Claudia Balducci
Journal:  Prion       Date:  2011-01-01       Impact factor: 3.931

Review 5.  Therapies for human prion diseases.

Authors:  Peter K Panegyres; Elizabeth Armari
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 6.  Prion protein and Alzheimer disease.

Authors:  Katherine A B Kellett; Nigel M Hooper
Journal:  Prion       Date:  2009-10-02       Impact factor: 3.931

7.  Identification of a novel endoplasmic reticulum stress response element regulated by XBP1.

Authors:  Michael Misiewicz; Marc-André Déry; Bénédicte Foveau; Julie Jodoin; Derek Ruths; Andréa C LeBlanc
Journal:  J Biol Chem       Date:  2013-06-04       Impact factor: 5.157

8.  Critical role of presenilin-dependent γ-secretase activity in DNA damage-induced promyelocytic leukemia protein expression and apoptosis.

Authors:  H Song; J Hyun Boo; K Ho Kim; C Kim; Y-E Kim; J-H Ahn; G Sun Jeon; H Ryu; D E Kang; I Mook-Jung
Journal:  Cell Death Differ       Date:  2013-01-11       Impact factor: 15.828

9.  Endoplasmic reticulum stress induces PRNP prion protein gene expression in breast cancer.

Authors:  Marc-André Déry; Julie Jodoin; Josie Ursini-Siegel; Olga Aleynikova; Cristiano Ferrario; Saima Hassan; Mark Basik; Andréa C LeBlanc
Journal:  Breast Cancer Res       Date:  2013-03-12       Impact factor: 6.466

10.  Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stage.

Authors:  Isobel J Whitehouse; J Scott Miners; Elizabeth B C Glennon; Patrick G Kehoe; Seth Love; Katherine A B Kellett; Nigel M Hooper
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.